Chlorsulfaquinoxaline | CAS#97919-22-7

MedKoo Cat#: 525319 | Name: Chlorsulfaquinoxaline

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Chlorsulfaquinoxaline is a immunosuppressive agent, inhibiting lymphocyte activation, inducing proteasomal degradation of the U2AF-related splicing factor coactivator of activating protein-1 and estrogen receptors (CAPERa).

Chemical Structure

Chlorsulfaquinoxaline

CAS#97919-22-7

Theoretical Analysis

MedKoo Cat#: 525319

Name: Chlorsulfaquinoxaline

CAS#: 97919-22-7

Chemical Formula: C14H11ClN4O2S

Exact Mass: 334.0291

Molecular Weight: 334.78

Elemental Analysis: C, 50.23; H, 3.31; Cl, 10.59; N, 16.74; O, 9.56; S, 9.58

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 385.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Chlorsulfaquinoxaline; NSC-339004; NSC 339004; NSC339004; Chloroquinoxaline sulfonamide;

IUPAC/Chemical Name

4-Amino-N-(5-chloroquinoxalin-2-yl)benzenesulfonamide

InChi Key

CTSNHMQGVWXIEG-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H11ClN4O2S/c15-11-2-1-3-12-14(11)17-8-13(18-12)19-22(20,21)10-6-4-9(16)5-7-10/h1-8H,16H2,(H,18,19)

SMILES Code

O=S(C1=CC=C(N)C=C1)(NC2=NC3=CC=CC(Cl)=C3N=C2)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot# M22C01E21

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 334.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Del Solar V, Quiñones-Lombraña A, Cabrera S, Padrón JM, Ríos-Luci C, Alvarez-Valdés A, Navarro-Ranninger C, Alemán J. Expanding the synthesis of new trans-sulfonamide platinum complexes: cytotoxicity, SAR, fluorescent cell assays and stability studies. J Inorg Biochem. 2013 Oct;127:128-40. doi: 10.1016/j.jinorgbio.2013.01.013. Epub 2013 Feb 8. PubMed PMID: 23474039. 2: Bekaii-Saab TS, Mortazavi A, Hicks LG, Zalupski M, Pelley RJ, Chan KK, Kraut EH. A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC). Invest New Drugs. 2006 Jul;24(4):343-6. PubMed PMID: 16446986. 3: Gao H, Yamasaki EF, Chan KK, Shen LL, Snapka RM. DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS. Mol Pharmacol. 2003 Jun;63(6):1382-8. PubMed PMID: 12761349. 4: Gao H, Yamasaki EF, Chan KK, Shen LL, Snapka RM. Chloroquinoxaline sulfonamide (NSC 339004) is a topoisomerase IIalpha/beta poison. Cancer Res. 2000 Nov 1;60(21):5937-40. PubMed PMID: 11085507. 5: Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47. PubMed PMID: 9262252. 6: Miller VA, Rigas JR, Tong WP, Reid JR, Pisters KM, Grant SC, Heelan RT, Kris MG. Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer. Cancer Chemother Pharmacol. 1997;40(5):415-8. PubMed PMID: 9272118. 7: Miller VA, Rigas JR, Grant SC, Pisters KM, Kris MG. New chemotherapeutic agents for non-small cell lung cancer. Chest. 1995 Jun;107(6 Suppl):306S-311S. Review. PubMed PMID: 7781411. 8: Rigas JR, Francis PA, Miller VA, Tong WP, Roistacher N, Kris MG, Orazem JP, Young CW, Warrell RP Jr. Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule. Cancer Chemother Pharmacol. 1995;35(6):483-8. PubMed PMID: 7882456. 9: Conley BA, O'Hara S, Wu S, Melink TJ, Parnes H, Pardoe E, Egorin MJ, Van Echo DA. Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol. 1995;37(1-2):139-49. PubMed PMID: 7497583. 10: Fisherman JS, Osborn BL, Chun HG, Plowman J, Smith AC, Christian MC, Zaharko DS, Shoemaker RH. Chloroquinoxaline sulfonamide: a sulfanilamide antitumor agent entering clinical trials. Invest New Drugs. 1993 Feb;11(1):1-9. Review. PubMed PMID: 8349430. 11: Rigas JR, Tong WP, Kris MG, Orazem JP, Young CW, Warrell RP Jr. Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide. Cancer Res. 1992 Dec 1;52(23):6619-23. PubMed PMID: 1423306. 12: Branda RF, Moore AL, McCormack JJ. Immunosuppressive properties of chloroquinoxaline sulfonamide. Biochem Pharmacol. 1989 Oct 15;38(20):3521-6. PubMed PMID: 2818644. 13: Branda RF, McCormack JJ, Perlmutter CA. Cellular pharmacology of chloroquinoxaline sulfonamide and a related compound in murine B16 melanoma cells. Biochem Pharmacol. 1988 Dec 1;37(23):4557-64. PubMed PMID: 3264501. 14: Shoemaker RH. New approaches to antitumor drug screening: the human tumor colony-forming assay. Cancer Treat Rep. 1986 Jan;70(1):9-12. PubMed PMID: 3943117.